SureTrader SureTrader
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

I don't know about the rest of you,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
pphmtoolong Member Profile
 
Followed By 26
Posts 3,574
Boards Moderated 0
Alias Born 07/17/06
160x600 placeholder
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 12/6/2016 4:05:00 PM
Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2017 After Market Close on December 12, 2016 "GlobeNewswire Inc." - 12/5/2016 4:05:00 PM
New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting An... "GlobeNewswire Inc." - 11/14/2016 8:05:00 AM
Preclinical Research Demonstrates Peregrine Pharmaceuticals’ PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-... "GlobeNewswire Inc." - 10/24/2016 8:05:00 AM
Form 8-K - Current report "Edgar (US Regulatory)" - 10/13/2016 4:45:00 PM
Form 8-K - Current report "Edgar (US Regulatory)" - 10/12/2016 2:25:00 PM
Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Pre... "GlobeNewswire Inc." - 10/10/2016 8:05:00 AM
Could these companies be setting up for a rebound? "InvestorsHub NewsWire" - 10/6/2016 8:00:00 AM
Peregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumo... "GlobeNewswire Inc." - 9/27/2016 8:05:00 AM
Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab a... "GlobeNewswire Inc." - 9/21/2016 8:05:00 AM
Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent Developments "GlobeNewswire Inc." - 9/8/2016 4:05:00 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 9/6/2016 4:05:00 PM
National Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavi... "GlobeNewswire Inc." - 9/6/2016 8:45:00 AM
Peregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016 "GlobeNewswire Inc." - 9/1/2016 4:05:00 PM
Avid Bioservices to Participate in Cambridge Healthtech Institute’s (CHI) 8th Annual The Bioprocessing Summit "GlobeNewswire Inc." - 8/9/2016 8:05:00 AM
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments "GlobeNewswire Inc." - 7/14/2016 4:05:00 PM
Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center "GlobeNewswire Inc." - 7/14/2016 8:05:00 AM
Peregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 201... "GlobeNewswire Inc." - 7/7/2016 4:05:00 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 6/2/2016 4:00:00 PM
Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Deve... "GlobeNewswire Inc." - 6/2/2016 8:05:00 AM
Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic... "GlobeNewswire Inc." - 4/20/2016 8:05:00 AM
Form 8-K - Current report "Edgar (US Regulatory)" - 4/12/2016 4:31:41 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 3/9/2016 7:46:45 PM
Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility "GlobeNewswire Inc." - 3/9/2016 7:46:43 PM
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016 "GlobeNewswire Inc." - 3/9/2016 7:46:38 PM
pphmtoolong   Tuesday, 04/24/12 10:44:52 AM
Re: None
Post # of 280988 
I don't know about the rest of you, but I bought this stock based on Thorpe's approved patents and the early Bavi clinical studies.

It seems that Peregrine management and BOD have done everything reasonable to forward the Bavi agenda given the limited financial resources available. Running the trials overseas in Georgia and India could not have been easy, but they did it and got promising results. As in many other cases Bavi may not pan out in later stage trials. I don't blame management for trying with Bavi, and I don't blame management for the perversity of Mother Nature. I could blame them for excessive optimism, but the science seemed sound to them just as it seemed sound to us.

I don't like that managment has diluted the heck out of our stock, but I really don't buy any of the alternative financing plans I've seen presented here. I am a retired CPA; so I have some confidence assessment on this point.

If Bavi finally hits it out of the park with second line NSCLC, there is still a chance for us to make money. Otherwise, this has been a very expensive lesson in wishful thinking on biotechs. I blame only myself if Peregrine flops. I never should have thrown so much money into such a crap shoot.

Paul

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist